본문 바로가기
KERD
논문KCI 등재

Functional Dyspepsia: Advances in Diagnosis and Therapy

Nicholas J. Talley
거트앤리버 소화기연관학회협의회|2017.05|Gut and Liver|제11권 제3호|pp. 349-357

1

조회

0

다운로드

2

인용

0

참고문헌

키워드

EpidemiologyFunctional dyspepsia

초록

Functional dyspepsia (FD) is a common but under-recognized syndrome comprising bothersome recurrent postprandial fullness, early satiety, or epigastric pain/burning. Epidemiologically, there are two clinically distinct FD syndromes (although these often overlap clinically): postprandial distress syndrome (PDS; comprising early satiety or meal-related fullness) and epigastric pain syndrome. Symptoms of gastroesophageal reflux disease overlap with FD more than expected by chance; a subset has pathological acid reflux. The pretest probability of FD in a patient who presents with classical FD symptoms and no alarm features is high, approximately 0.7. Coexistent heartburn should not lead to the exclusion of FD as a diagnosis. One of the most exciting observations in FD has been the consistent finding of increased duodenal eosinophilia, notably in PDS. Small bowel homing T cells, signaling intestinal inflammation, and increased cytokines have been detected in the circulation, and elevated tumor necrosis factor-α levels have been significantly correlated with increased anxiety. Postinfectious gastroenteritis is a risk factor for FD. Therapeutic options remain limited and provide only symptomatic benefit in most cases. Only one therapy is known to change the natural history of FD–Helicobacter pylori eradication. Treatment of duodenal eosinophilia is under investigation.

Abstract

Functional dyspepsia (FD) is a common but under-recognized syndrome comprising bothersome recurrent postprandial fullness, early satiety, or epigastric pain/burning. Epidemiologically, there are two clinically distinct FD syndromes (although these often overlap clinically): postprandial distress syndrome (PDS; comprising early satiety or meal-related fullness) and epigastric pain syndrome. Symptoms of gastroesophageal reflux disease overlap with FD more than expected by chance; a subset has pathological acid reflux. The pretest probability of FD in a patient who presents with classical FD symptoms and no alarm features is high, approximately 0.7. Coexistent heartburn should not lead to the exclusion of FD as a diagnosis. One of the most exciting observations in FD has been the consistent finding of increased duodenal eosinophilia, notably in PDS. Small bowel homing T cells, signaling intestinal inflammation, and increased cytokines have been detected in the circulation, and elevated tumor necrosis factor-α levels have been significantly correlated with increased anxiety. Postinfectious gastroenteritis is a risk factor for FD. Therapeutic options remain limited and provide only symptomatic benefit in most cases. Only one therapy is known to change the natural history of FD–Helicobacter pylori eradication. Treatment of duodenal eosinophilia is under investigation.

참고문헌 (103)

  1. Talley NJ, "Functional dyspepsia", N Engl J Med, 373, pp.1853~1863 (2015)
  2. Tack J, "Functional gastroduodenal disorders", Gastroenterology, 130, pp.1466~1479 (2006)
  3. Camilleri M, "Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study", Clin Gastroenterol Hepatol, 3, pp.543~552 (2005)
  4. Ford AC, "Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis", Gut, 64, pp.1049~1057 (2015)
  5. Ford AC, "What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis", Clin Gastroenterol Hepatol, 8, pp.830~837.e2 (2010)
  6. Pleyer C, "Overdiagnosis of gastroesophageal reflux disease and underdiagnosis of functional dyspepsia in a USA community", Neurogastroenterol Motil, 26, pp.1163~1171 (2014)
  7. Jones MP, "The overlap of atopy and functional gastrointestinal disorders among 23,471 patients in primary care", Aliment Pharmacol Ther, 40, pp.382~391 (2014)
  8. Talley NJ, "Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based casecontrol study", Clin Gastroenterol Hepatol, 5, pp.1175~1183 (2007)
  9. Ford AC, "Increased prevalence of autoimmune diseases in functional gastrointestinal disorders: case-control study of 23471 primary care patients", Aliment Pharmacol Ther, 40, pp.827~834 (2014)
  10. Aro P, "Functional dyspepsia impairs quality of life in the adult population", Aliment Pharmacol Ther, 33, pp.1215~1224 (2011)
  11. Haag S, "Impairment of health-related quality of life in functional dyspepsia and chronic liver disease: the influence of depression and anxiety", Aliment Pharmacol Ther, 27, pp.561~571 (2008)
  12. Lacy BE, "Functional dyspepsia: the economic impact to patients", Aliment Pharmacol Ther, 38, pp.170~177 (2013)
  13. Brook RA, "Functional dyspepsia impacts absenteeism and direct and indirect costs", Clin Gastroenterol Hepatol, 8, pp.498~503 (2010)
  14. Brook RA, "Excess comorbidity prevalence and cost associated with functional dyspepsia in an employed population", Dig Dis Sci, 57, pp.109~118 (2012)
  15. Chang JY, "Impact of functional gastrointestinal disorders on survival in the community", Am J Gastroenterol, 105, pp.822~832 (2010)
  16. Moayyedi P, "Can the clinical history distinguish between organic and functional dyspepsia", JAMA, 295, pp.1566~1576 (2006)
  17. Ford AC, "The Rome III criteria for the diagnosis of functional dyspepsia in secondary care are not superior to previous definitions", Gastroenterology, 146, pp.932~940 (2014)
  18. Vakil N, "Symptom overlap between postprandial distress and epigastric pain syndromes of the Rome III dyspepsia classification", Am J Gastroenterol, 108, pp.767~774 (2013)
  19. Tack J, "Functional dyspepsia: symptoms, definitions and validity of the Rome III criteria", Nat Rev Gastroenterol Hepatol, 10, pp.134~141 (2013)
  20. Bisschops R, "Relationship between symptoms and ingestion of a meal in functional dyspepsia", Gut, 57, pp.1495~1503 (2008)
  21. Gururatsakul M, "Complicated and uncomplicated peptic ulcer disease: altered symptom response to a nutrient challenge linked to gastric motor dysfunction", Digestion, 89, pp.239~246 (2014)
  22. Gururatsakul M, "The ageing gut: diminished symptom response to a standardized nutrient stimulus", Neurogastroenterol Motil, 22, pp.246-e77~ (2010)
  23. Keshteli AH, "Patterns of dietary behaviours identified by latent class analysis are associated with chronic uninvestigated dyspepsia", Br J Nutr, 113, pp.803~812 (2015)
  24. Jones MP, "Community subgroups in dyspepsia and their association with weight loss", Am J Gastroenterol, 103, pp.2051~2060 (2008)
  25. Talley NJ, "Functional dyspepsia, delayed gastric emptying, and impaired quality of life", Gut, 55, pp.933~939 (2006)
  26. Stanghellini V, "Gastroparesis: separate entity or just a part of dyspepsia", Gut, 63, pp.1972~1978 (2014)
  27. Jung HK, "The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006", Gastroenterology, 136, pp.1225~1233 (2009)
  28. Savarino E, "Functional heartburn has more in common with functional dyspepsia than with nonerosive reflux disease", Gut, 58, pp.1185~1191 (2009)
  29. Pauwels A, "The gastric accommodation response to meal intake determines the occurrence of transient lower esophageal sphincter relaxations and reflux events in patients with gastro-esophageal reflux disease", Neurogastroenterol Motil, 26, pp.581~588 (2014)
  30. Choung RS, "Cyclic vomiting syndrome and functional vomiting in adults: association with cannabinoid use in males", Neurogastroenterol Motil, 24, pp.20-e1~ (2012)
  31. Choung RS, "Associations between medication use and functional gastrointestinal disorders: a population-based study", Neurogastroenterol Motil, 25, pp.413-e298~ (2013)
  32. Choung RS, "Opioid bowel dysfunction and narcotic bowel syndrome: a population-based study", Am J Gastroenterol, 104, pp.1199~1204 (2009)
  33. Gathaiya N, "Novel associations with dyspepsia: a communitybased study of familial aggregation, sleep dysfunction and somatization", Neurogastroenterol Motil, 21, pp.922-e69~ (2009)
  34. Holtmann G, "G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia", Gastroenterology, 126, pp.971~979 (2004)
  35. Shimpuku M, "G-protein beta3 subunit 825CC genotype is associated with postprandial distress syndrome with impaired gastric emptying and with the feeling of hunger in Japanese", Neurogastroenterol Motil, 23, pp.1073~1080 (2011)
  36. Singh R, "Functional dyspepsia is associated with GNbeta3 C825T and CCK-AR T", C polymorphism, 2016, pp.28, 226~232
  37. Kourikou A, "Gene polymorphisms associated with functional dyspepsia", World J Gastroenterol, 21, pp.7672~7682 (2015)
  38. Aro P, "Anxiety is linked to new-onset dyspepsia in the Swedish population: a 10-year follow-up study", Gastroenterology, 148, pp.928~937 (2015)
  39. Koloski NA, "The brain–gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study", Gut, 61, pp.1284~1290 (2012)
  40. Gracie DJ, "No increase in prevalence of somatization in functional vs organic dyspepsia: a crosssectional survey", Neurogastroenterol Motil, 27, pp.1024~1031 (2015)
  41. Koloski NA, "A history of abuse in community subjects with irritable bowel syndrome and functional dyspepsia: the role of other psychosocial variables", Digestion, 72, pp.86~96 (2005)
  42. Haag S, "Symptom patterns in functional dyspepsia and irritable bowel syndrome: relationship to disturbances in gastric emptying and response to a nutrient challenge in consulters and non-consulters", Gut, 53, pp.1445~1451 (2004)
  43. Haag S, "Is there any association between disturbed gastrointestinal visceromotor and sensory function and impaired quality of life in functional dyspepsia", Neurogastroenterol Motil, 22, pp.262~279.e79 (2010)
  44. Van Oudenhove L, "Determinants of symptoms in functional dyspepsia: gastric sensorimotor function, psychosocial factors or somatisation", Gut, 57, pp.1666~1673 (2008)
  45. Ly HG, "Acute anxiety and anxiety disorders are associated with impaired gastric accommodation in patients with functional dyspepsia", Clin Gastroenterol Hepatol, 13, pp.1584~1591.e3 (2015)
  46. di Stefano M, "Prolonged duodenal acid perfusion and dyspeptic symptom occurrence in healthy volunteers", Neurogastroenterol Motil, 21, pp.712-e40~ (2009)
  47. Vanuytsel T, "Role of duodenal mucosal nerve endings in the acidinduced duodenogastric sensorimotor reflex: effect of benzocaine in healthy humans", Neurogastroenterol Motil, 25, pp.e353~e361 (2013)
  48. Kazemi M, "Changes in serum ghrelin level in relation to meal-time in patients with functional dyspepsia", United European Gastroenterol J, 3, pp.11~16 (2015)
  49. Pilichiewicz AN, "Functional dyspepsia is associated with a greater symptomatic response to fat but not carbohydrate, increased fasting and postprandial CCK, and diminished PYY", Am J Gastroenterol, 103, pp.2613~2623 (2008)
  50. van Boxel OS, "Functional dyspepsia patients have lower mucosal cholecystokinin concentrations in response to duodenal lipid", Eur J Gastroenterol Hepatol, 26, pp.205~212 (2014)
  51. Bharucha AE, "Increased nutrient sensitivity and plasma concentrations of enteral hormones during duodenal nutrient infusion in functional dyspepsia", Am J Gastroenterol, 109, pp.1910~1920 (2014)
  52. Friesen CA, "Eosinophils and mast cells as therapeutic targets in pediatric functional dyspepsia", World J Gastrointest Pharmacol Ther, 4, pp.86~96 (2013)
  53. Walker MM, "Duodenal eosinophilia and early satiety in functional dyspepsia: confirmation of a positive association in an Australian cohort", J Gastroenterol Hepatol, 29, pp.474~479 (2014)
  54. Nwokediuko SC, "High degree of duodenal inflammation in Nigerians with functional dyspepsia", Clin Exp Gastroenterol, 7, pp.7~12 (2013)
  55. Walker MM, "Implications of eosinophilia in the normal duodenal biopsy: an association with allergy and functional dyspepsia", Aliment Pharmacol Ther, 31, pp.1229~1236 (2010)
  56. Walker MM, "Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia", Aliment Pharmacol Ther, 29, pp.765~773 (2009)
  57. Vanheel H, "Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia", Gut, 63, pp.262~271 (2014)
  58. Cirillo C, "Evidence for neuronal and structural changes in submucous ganglia of patients with functional dyspepsia", Am J Gastroenterol, 110, pp.1205~1215 (2015)
  59. Esmaillzadeh A, "Smoking status and prevalence of upper gastrointestinal disorders", Digestion, 89, pp.282~290 (2014)
  60. Liebregts T, "Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia", Am J Gastroenterol, 106, pp.1089~1098 (2011)
  61. Keely S, "Immune dysregulation in the functional gastrointestinal disorders", Eur J Clin Invest, 45, pp.1350~1359 (2015)
  62. Koloski NA, "Identification of early environmental risk factors for irritable bowel syndrome and dyspepsia", Neurogastroenterol Motil, 27, pp.1317~1325 (2015)
  63. Boettcher E, "Dietary proteins and functional gastrointestinal disorders", Am J Gastroenterol, 108, pp.728~736 (2013)
  64. Paula H, "Non-enteric infections, antibiotic use, and risk of development of functional gastrointestinal disorders", Neurogastroenterol Motil, 27, pp.1580~1586 (2015)
  65. Walker MM, "Review article: bacteria and pathogenesis of disease in the upper gastrointestinal tract: beyond the era of Helicobacter pylori", Aliment Pharmacol Ther, 39, pp.767~779 (2014)
  66. Futagami S, "Systematic review with metaanalysis: post-infectious functional dyspepsia", Aliment Pharmacol Ther, 41, pp.177~188 (2015)
  67. Tuteja AK, "Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA", Dig Dis Sci, 53, pp.271~276 (2008)
  68. Futagami S, "Migration of eosinophils and CCR2-", CD68-double positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia, 2010, pp.105, 1835~1842
  69. Tack J, "Clinical and pathophysiological characteristics of acute-onset functional dyspepsia", Gastroenterology, 122, pp.1738~1747 (2002)
  70. Dizdar V, "Relative importance of abnormalities of CCK and 5-HT (serotonin) in Giardia-induced postinfectious irritable bowel syndrome and functional dyspepsia", Aliment Pharmacol Ther, 31, pp.883~891 (2010)
  71. Spiller R, "Postinfectious functional dyspepsia and postinfectious irritable bowel syndrome: different symptoms but similar risk factors", Gastroenterology, 138, pp.1660~1663 (2010)
  72. Talley NJ, "Predictors of the placebo response in functional dyspepsia", Aliment Pharmacol Ther, 23, pp.923~936 (2006)
  73. Pilichiewicz AN, "Relationship between symptoms and dietary patterns in patients with functional dyspepsia", Clin Gastroenterol Hepatol, 7, pp.317~322 (2009)
  74. Zala AV, "Emerging drugs for functional dyspepsia", Expert Opin Emerg Drugs, 20, pp.221~233 (2015)
  75. Moshiree B, "An update on current pharmacotherapy options for dyspepsia", Expert Opin Pharmacother, 14, pp.1737~1753 (2013)
  76. Lacy BE, "Review article: current treatment options and management of functional dyspepsia", Aliment Pharmacol Ther, 36, pp.3~15 (2012)
  77. Yazdanbod A, "Effect of Helicobacter pylori eradication in Iranian patients with functional dyspepsia: a prospective, randomized, placebo-controlled trial", Arch Med Sci, 11, pp.964~969 (2015)
  78. Mazzoleni LE, "Helicobacter pylori eradication in functional dyspepsia: HEROES trial", Arch Intern Med, 171, pp.1929~1936 (2017)
  79. Talley NJ, "American gastroenterological association technical review on the evaluation of dyspepsia", Gastroenterology, 129, pp.1756~1780 (2005)
  80. Sugano K, "Kyoto global consensus report on Helicobacter pylori gastritis", Gut, 64, pp.1353~1367 (2015)
  81. Holtmann G, "Functional dyspepsia", Curr Opin Gastroenterol, 31, pp.492~498 (2015)
  82. Moayyedi P, "The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis", Gastroenterology, 127, pp.1329~1337 (2004)
  83. Talley NJ, "Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response?", Aliment Pharmacol Ther, 26, pp.673~682 (2007)
  84. Friesen CA, "Mucosal eosinophilia and response to H1", H2 antagonist and cromolyn therapy in pediatric dyspepsia, 2006, pp.45, 143~147
  85. Molina-Infante J, "Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression", Aliment Pharmacol Ther, 40, pp.955~965 (2014)
  86. Hondeghem LM, "Domperidone: limited benefits with significant risk for sudden cardiac death", J Cardiovasc Pharmacol, 61, pp.218~225 (2013)
  87. Talley NJ, "Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials", Gut, 57, pp.740~746 (2008)
  88. Huang X, "Itopride therapy for functional dyspepsia: a meta-analysis", World J Gastroenterol, 18, pp.7371~7377 (2012)
  89. Holtmann G, "A placebo- controlled trial of itopride in functional dyspepsia", N Engl J Med, 354, pp.832~840 (2006)
  90. Amano T, "Effect of 5-hydroxytryptamine receptor 4 agonist mosapride on human gastric accommodation", Neurogastroenterol Motil, 27, pp.1303~1309 (2015)
  91. Bang CS, "Mosapride treatment for functional dyspepsia: a meta-analysis", J Gastroenterol Hepatol, 30, pp.28~42 (2015)
  92. Matsueda K, "A placebocontrolled trial of acotiamide for meal-related symptoms of functional dyspepsia", Gut, 61, pp.821~828 (2012)
  93. Xiao G, "Efficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysis", ScientificWorld- Journal, 2014 (2014)
  94. Tack J, "Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia", Clin Gastroenterol Hepatol, 10, pp.1239~1245 (2012)
  95. Talley NJ, "Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study", Gastroenterology, 149, pp.340~349.e2 (2015)
  96. Alexander C Ford, "Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis", Gut, 66(3), pp.411~420 (2017), BMJ[DOI]
  97. Tack J, "Efficacy of mirtazapine in patients with functional dyspepsia and weight loss", Clin Gastroenterol Hepatol, 14, pp.385~392.e4 (2016)
  98. Friesen CA, "Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia", J Pediatr Gastroenterol Nutr, 38, pp.343~351 (2004)
  99. Pilichiewicz AN, "Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men", Am J Gastroenterol, 102, pp.1276~1283 (2007)
  100. Holtmann G, "Herbal medicines for the treatment of functional and inflammatory bowel disorders", Clin Gastroenterol Hepatol, 13, pp.422~432 (2015)
  101. Kim KN, "Efficacy of acupuncture treatment for functional dyspepsia: a systematic review and meta-analysis", Complement Ther Med, 23, pp.759~766 (2015)
  102. Haag S, "Is there a benefit from intensified medical and psychological interventions in patients with functional dyspepsia not responding to conventional therapy", Aliment Pharmacol Ther, 25, pp.973~986 (2007)
  103. Ford AC, "Effect of dyspepsia on survival: a longitudinal 10-year follow-up study", Am J Gastroenterol, 107, pp.912~921 (2012)

관련 논문AI추천

Functional dyspepsia: new insights into pathogenesis and therapyNicholas J Talley대한내과학회 · The Korean Journal of Internal Medicine2016 · 제31권 제3호기능성 소화불량 환자의 증상, 위내시경 소견 및 위전도 지표 간 연관성: 후향적 단면 연구김소연, 박규태한의병리학회 · 동의생리병리학회지2025 · 제39권 제6호기능성 소화불량증의 임상 진료 지침 개정안 2020강승주, 권중구, 김성은, 김준성, 박종규, 방기배, 백명기, 송경호, 신정은, 신철민, 오정환, 이주엽, 임현철, 정경원, 정혜경, 태정현, 대한소화기기능성질환･운동학회 기능성 소화불량증위원회⋅진료지침위원회대한내과학회 · 대한내과학회지2021 · 제96권 제2호The Speed of Eating and Functional Dyspepsia in Young Women김경묵, 김재준, 손희정, 신동혁, 이종철, 이풍렬, Dong Hyun Sinn, Seong Woo Lim거트앤리버 소화기연관학회협의회 · Gut and Liver2010 · 제4권 제2호Analysis of the Gastrointestinal Symptoms of Uninvestigated Dyspepsia and Irritable Bowel SyndromeHiroto Miwa, Kazutoshi Hori, Takayuki Matsumoto거트앤리버 소화기연관학회협의회 · Gut and Liver2009 · 제3권 제3호Associations among the Duodenal Ecosystem, Gut Microbiota, and Nutrient Intake in Functional Dyspepsia김상훈, 이정은, Choi Yura, Kim Hojun, Lim Eui Yeon, Nam Young-Do, Oh Jihong, Song Eun-Ji거트앤리버 소화기연관학회협의회 · Gut and Liver2024 · 제18권 제4호

이 간행물의 다른 논문 (19건)

Clinical Considerations of Silent Gastroesophageal Reflux Disease in Morbidly Obese Patients김성은pp. 315-316Micronutrients Should Be Monitored in the Real Practice for Korean Inflammatory Bowel Disease Patients김성은pp. 317-318Disability Index as a New Outcome Measure in Patients with Inflammatory Bowel Disease조영석, 최현호pp. 319-320Can Magnetic Resonance Elastography Fill a Niche in the Market for Noninvasive Assessment of Liver Fibrosis?김승업pp. 321-322Obesity-Related Digestive Diseases and Their Pathophysiology남수연pp. 323-334
원문 보기